Released Mar 16, 2017, after the close
10-K filed Mar 16, 2017, 75 days after period end · 0001564590-17-004614
Q4 2016 · 10-K
Revenue$1.03M$1.03M −4.6% vs Q4 2015+0.1% vs Q3 2016
Net Income-$7.94M-$7.94M N/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.21-$0.21 N/M vs Q4 2015N/M vs Q3 2016
Operating Incomederived-$7,654,000N/M
Operating Cash Flowderived-$7,551,000N/M
Free Cash Flowderived-$7,591,000N/M
Margins · derived
Operating margin-745.3%−102.9 pt vs Q4 2015
Net margin-773.1%−81.1 pt vs Q4 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.08M | — | $0.00 |
| Net Income | -$7.94M | -$7.45M | -$6.23M | -$5.74M |
| EPS Diluted | -$0.21 | -$0.26 | -$0.30 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR